Medicare Should Not Cover Aducanumab as a Treatment for Alzheimer's Disease

被引：11
|
作者：
Moghavem, Nuriel [1 ]
Henderson, Victor W. [2 ,3 ]
Greicius, Michael D. [4 ]
机构：
[1] Univ Southern Calif, Keck Sch Med, Dept Neurol, Los Angeles, CA 90007 USA
[2] Stanford Univ, Dept Epidemiol & Populat Hlth, Stanford, CA 94305 USA
[3] Stanford Univ, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA
[4] Stanford Univ, Dept Neurol & Neurol Sci, Sch Med, Stanford, CA 94305 USA
来源：
ANNALS OF NEUROLOGY | 2021年 / 90卷 / 03期
关键词：
POSITRON-EMISSION-TOMOGRAPHY;
D O I：
10.1002/ana.26167
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：331 / 333
页数：3
相关论文
共 50 条
  • [41] Addendum: The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
    Jeff Sevigny
    Ping Chiao
    Thierry Bussière
    Paul H. Weinreb
    Leslie Williams
    Marcel Maier
    Robert Dunstan
    Stephen Salloway
    Tianle Chen
    Yan Ling
    John O’Gorman
    Fang Qian
    Mahin Arastu
    Mingwei Li
    Sowmya Chollate
    Melanie S. Brennan
    Omar Quintero-Monzon
    Robert H. Scannevin
    H. Moore Arnold
    Thomas Engber
    Kenneth Rhodes
    James Ferrero
    Yaming Hang
    Alvydas Mikulskis
    Jan Grimm
    Christoph Hock
    Roger M. Nitsch
    Alfred Sandrock
    Nature, 2017, 546 : 564 - 564
  • [42] Approval of Aducanumab for Alzheimer Disease-the FDA's Perspective
    Dunn, Billy
    Stein, Peter
    Cavazzoni, Patrizia
    JAMA INTERNAL MEDICINE, 2021, 181 (10) : 1276 - 1278
  • [43] Regulatory decisions diverge over aducanumab for Alzheimer's disease
    Lythgoe, Mark P.
    Jenei, Kristina
    Prasad, Vinay
    BMJ-BRITISH MEDICAL JOURNAL, 2022, 376
  • [44] Lessons Learned from Approval of Aducanumab for Alzheimer's Disease
    Heidebrink, Judith L.
    Paulson, Henry L.
    ANNUAL REVIEW OF MEDICINE, 2024, 75 : 99 - 111
  • [45] Aducanumab: a new phase in therapeutic development for Alzheimer's disease?
    Lalli, Giovanna
    Schott, Jonathan M.
    Hardy, John
    De Strooper, Bart
    EMBO MOLECULAR MEDICINE, 2021, 13 (08)
  • [46] An Appropriate Use of Accelerated Approval - Aducanumab for Alzheimer's Disease
    Dunn, Billy
    Stein, Peter
    Temple, Robert
    Cavazzoni, Patrizia
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (09): : 856 - 857
  • [47] Controversy and Progress in Alzheimer's Disease - FDA Approval of Aducanumab
    Rabinovici, Gil D.
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (09): : 771 - 774
  • [48] What does aducanumab treatment of Alzheimer's disease mean for research on vascular cognitive disorders?
    Wallin, Anders
    Alladi, Suvarna
    Black, Sandra E.
    Chen, Christopher
    Greenberg, Steven M.
    Gustafson, Deborah
    Isaacs, Jeremy D.
    Jokinen, Hanna
    Kalaria, Raj
    Mok, Vincent
    Pantoni, Leonardo
    Pasquier, Florence
    Roman, Gustavo C.
    Rosenberg, Gary A.
    Schmidt, Reinhold
    Smith, Eric E.
    Hainsworth, Atticus H.
    CEREBRAL CIRCULATION - COGNITION AND BEHAVIOR, 2022, 3
  • [49] Is Aducanumab treatment developed to prevent progression of Alzheimer's disease cost-effective in Turkey?
    Vahit Yigit
    Selin Kalender
    Iskender Cetinturk
    Cost Effectiveness and Resource Allocation, 21
  • [50] Is Aducanumab treatment developed to prevent progression of Alzheimer's disease cost-effective in Turkey?
    Yigit, Vahit
    Kalender, Selin
    Cetinturk, Iskender
    COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2023, 21 (01)
12345